Clinical Trial Update: Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea [Phase 3]

View source ↗

Summary

A Phase 3 study of Azilect (rasagiline) in levodopa-treated Parkinson's disease patients with motor fluctuations in Korea has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Azilect (rasagiline)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-12-03